Equasens Group's 2024 half-year results show decline in revenue and profit, but positive profit margin.

From GlobeNewswire: 2024-09-27 12:00:00

Equasens Group’s half-year results for 2024 show a decrease in revenue to €108.0m, down 4.1%. Current Operating Income also declined to €20.9m, a decrease of 24.1%. Net Profit attributable to the Group was €17.2m, down 21.8%. Despite these challenges, Equasens maintained a positive profit margin with COI/Sales ratio at 19.3%.

The Pharmagest division saw a contraction in earnings due to lower sales in France, resulting in a COI/Sales ratio of 17.2%. Strategic investments in Axigate Link for Nursing Homes in Europe affected results, but the profit margin remained high at 28.6%. The E-Connect division experienced a decline in current operating income due to lower sales, with a COI/Sales ratio of 45.4%.

In the Medical Solutions division, earnings were impacted by investments in new software solutions, resulting in no reported COI/Sales ratio. The Fintech division showed improvement in earnings by €0.3m, with no reported COI/Sales ratio. Equasens Group maintained a positive cash flow trend at €20.8m and continued financial investments in acquisitions and capital expenditures.

Looking ahead, Equasens Group forecasts a return to revenue growth in the second half of 2024 and an acceleration in 2025. The Group will continue to invest in R&D, infrastructure, and sales forces in France and Europe to generate a return on investment from 2025 onwards. Equasens Group is focused on patients and interoperability to seize opportunities for growth.

With more than 1,300 employees, Equasens Group is a key player in the European healthcare sector, providing software and hardware solutions to healthcare professionals in primary and secondary care sectors. Operations in several European countries make Equasens Group uniquely positioned to benefit people with cutting-edge technology.



Read more at GlobeNewswire:: Equasens: 2024 half-year results